Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT03369964
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 48
- Registration Number
- NCT03362723
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Yale Cancer Center; Medical Oncology, New Haven, Connecticut, United States
🇨🇦Jewish General Hospital / McGill University, Montreal, Quebec, Canada
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)
- Conditions
- Huntington's Disease
- Interventions
- Drug: RO7234292 (RG6042)
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT03342053
- Locations
- 🇬🇧
Central Manchester University Hospitals NHS Foundation Trust; Manchester Centre for Genomic Medicine, Manchester, United Kingdom
🇬🇧Leonard Wolfson Experimental Neurology Centre, London, United Kingdom
🇩🇪Universitaetsklinikum Ulm, Ulm, Germany
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Other: Radiation
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 314
- Registration Number
- NCT03337698
- Locations
- 🇺🇸
Christiana Care Health Services, Newark, Delaware, United States
🇺🇸Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas, Nevada, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 579
- Registration Number
- NCT03337724
- Locations
- 🇩🇪
Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie, Recklinghausen, Germany
🇺🇸Kaiser Permanente - Roseville, Roseville, California, United States
🇺🇸Kaiser Permanente - South San Francisco, South San Francisco, California, United States
Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy
- Conditions
- Neoplasms
- Interventions
- Procedure: Biopsy
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT03333655
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸UCSF Comp Canc Ctr, San Francisco, California, United States
🇺🇸Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology, Saint Louis, Missouri, United States
A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina
- Conditions
- Urothelial Carcinoma
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 13
- Registration Number
- NCT03330886
- Locations
- 🇦🇷
Productos Roche S.A. Quimica e Industrial, División Farmacéutica, Buenos Aires, Argentina
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT03330990
- Locations
- 🇺🇸
SCRI-Denver Drug Development Program, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists - Sarasota (North Catttlemen Rd), Sarasota, Florida, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina
- Conditions
- Carcinoma, Non-small-cell Lung
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 44
- Registration Number
- NCT03321695
- Locations
- 🇦🇷
Productos Roche S.A. Quimica e Industrial, División Farmacéutica, Buenos Aires, Argentina
Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 85
- Registration Number
- NCT03315455
- Locations
- 🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing City, China
🇨🇳Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai City, China
🇭🇰Queen Mary Hospital, Hong kong, Hong Kong